News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,407 Results
Type
Article (42411)
Company Profile (276)
Press Release (688706)
Multimedia
Podcasts (102)
Webinars (22)
Section
Business (206102)
Career Advice (2125)
Deals (35733)
Drug Delivery (126)
Drug Development (81763)
Employer Resources (177)
FDA (16554)
Job Trends (15092)
News (348604)
Policy (32932)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2634)
Accelerated approval (44)
Adcomms (25)
Allergies (160)
Alliances (49963)
ALS (195)
Alzheimer's disease (1760)
Antibody-drug conjugate (ADC) (375)
Approvals (16867)
Artificial intelligence (613)
Autoimmune disease (228)
Automation (50)
Bankruptcy (365)
Best Places to Work (11737)
BIOSECURE Act (21)
Biosimilars (203)
Biotechnology (184)
Bladder cancer (177)
Brain cancer (65)
Breast cancer (687)
Cancer (5337)
Cardiovascular disease (446)
Career advice (1803)
Career pathing (42)
CAR-T (303)
CDC (54)
Celiac Disease (2)
Cell therapy (807)
Cervical cancer (41)
Clinical research (70434)
Collaboration (1934)
Company closure (4)
Compensation (1273)
Complete response letters (70)
COVID-19 (2742)
CRISPR (101)
C-suite (1015)
Cystic fibrosis (148)
Data (7070)
Decentralized trials (3)
Denatured (28)
Depression (156)
Dermatology (58)
Diabetes (550)
Diagnostics (6889)
Digital health (54)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (298)
Drug pricing (201)
Drug shortages (29)
Duchenne muscular dystrophy (267)
Earnings (91226)
Editorial (62)
Employer branding (22)
Employer resources (155)
Events (119040)
Executive appointments (1068)
FDA (19988)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1651)
Gene editing (215)
Generative AI (53)
Gene therapy (667)
GLP-1 (1030)
Government (4753)
Grass and pollen (6)
Guidances (396)
Healthcare (19110)
HIV (73)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (279)
Immuno-oncology (84)
Indications (157)
Infectious disease (3055)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (274)
Interviews (341)
IPO (16688)
IRA (51)
Job creations (3671)
Job search strategy (1493)
JPM (62)
Kidney cancer (18)
Labor market (93)
Layoffs (561)
Leadership (38)
Legal (7991)
Liver cancer (99)
Longevity (28)
Lung cancer (718)
Lymphoma (409)
Machine learning (53)
Management (60)
Manufacturing (924)
MASH (184)
Medical device (13958)
Medtech (14035)
Mergers & acquisitions (20209)
Metabolic disorders (1424)
mRNA (177)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (395)
Neuropsychiatric disorders (99)
Neuroscience (3168)
Neurotech (1)
NextGen: Class of 2026 (6626)
Non-profit (4600)
Now hiring (73)
Obesity (671)
Opinion (290)
Ovarian cancer (186)
Pain (228)
Pancreatic cancer (256)
Parkinson's disease (342)
Partnered (34)
Patents (552)
Patient recruitment (596)
Peanut (60)
People (59954)
Pharmaceutical (60)
Pharmacy benefit managers (34)
Phase 1 (21976)
Phase 2 (31012)
Phase 3 (23105)
Pipeline (7137)
Policy (314)
Postmarket research (2570)
Preclinical (9317)
Press Release (65)
Prostate cancer (274)
Psychedelics (51)
Radiopharmaceuticals (306)
Rare diseases (1001)
Real estate (5995)
Recruiting (71)
Regulatory (25084)
Reports (55)
Research institute (2455)
Resumes & cover letters (367)
Rett syndrome (32)
RNA editing (17)
RSV (85)
Schizophrenia (163)
Series A (276)
Series B (206)
Service/supplier (11)
Sickle cell disease (111)
Special edition (29)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3659)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (87)
The Weekly (72)
Vaccines (1064)
Venture capital (99)
Weight loss (425)
Women's health (110)
Worklife (20)
Date
Last 7 days (640)
Last 30 days (2444)
Last 365 days (30202)
2026 (8062)
2025 (30495)
2024 (35452)
2023 (40346)
2022 (51440)
2021 (56007)
2020 (54441)
2019 (47095)
2018 (35400)
2017 (32354)
2016 (31757)
2015 (37803)
2014 (31545)
2013 (26566)
2012 (28792)
2011 (29440)
2010 (27465)
Location
Africa (754)
Alabama (90)
Alaska (7)
Arizona (335)
Arkansas (13)
Asia (39866)
Australia (6530)
California (12328)
Canada (3513)
China (1248)
Colorado (526)
Connecticut (533)
Delaware (366)
Europe (86253)
Florida (1852)
Georgia (396)
Hawaii (3)
Idaho (62)
Illinois (966)
India (82)
Indiana (560)
Iowa (22)
Japan (490)
Kansas (131)
Kentucky (44)
Louisiana (39)
Maine (73)
Maryland (1492)
Massachusetts (8858)
Michigan (347)
Minnesota (681)
Mississippi (6)
Missouri (140)
Montana (33)
Nebraska (29)
Nevada (136)
New Hampshire (83)
New Jersey (3274)
New Mexico (28)
New York (3258)
North Carolina (1571)
North Dakota (8)
Northern California (6090)
Ohio (367)
Oklahoma (24)
Oregon (41)
Pennsylvania (2489)
Puerto Rico (26)
Rhode Island (51)
South America (1138)
South Carolina (76)
South Dakota (1)
Southern California (4846)
Tennessee (200)
Texas (1939)
United States (43707)
Utah (369)
Vermont (1)
Virginia (294)
Washington D.C. (80)
Washington State (989)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
731,407 Results for "deep blue inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
January 7, 2026
·
1 min read
·
Tristan Manalac
Special edition
Deep Dive: Chinese Biotech Innovation Can’t Be Stopped
In this deep dive,
BioSpace
investigates China’s rise as a biotech powerhouse.
October 27, 2025
·
3 min read
·
Annalee Armstrong
Cardiovascular disease
Deep Dive: Oral Obesity Drugs on the Cusp
In this deep dive,
BioSpace
explores the next big thing in obesity.
September 18, 2025
·
3 min read
·
Heather McKenzie
Special edition
Deep Dive: Women in Biopharma
BioSpace
did a deep dive into biopharma female executives who navigated difficult markets to lead their companies to high-value exits.
August 27, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Radial Announces Publication of Landmark Study of Accelerated Deep TMS for Depression
March 13, 2026
·
2 min read
Press Releases
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
February 23, 2026
·
3 min read
Immunology and inflammation
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage
The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.
February 11, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Blue Circle Health Earns National Recognition from the American Diabetes Association
March 3, 2026
·
4 min read
Press Releases
Dark Blue Therapeutics acquired by Amgen for up to $840 million
January 7, 2026
·
4 min read
Press Releases
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
January 7, 2026
·
8 min read
1 of 73,141
Next
